Regeneron Phase 2 trial shows trevogrumab prevents muscle loss during GLP-1 weight loss
REGN•Regeneron said its Phase 2 COURAGE trial found trevogrumab prevented 70% of muscle loss associated with semaglutide treatment. The company plans a Phase 2 trial of trevogrumab with GLP-1 therapies in older adults.
1. Trial findings
Regeneron said its Phase 2 COURAGE trial found trevogrumab prevented 70% of muscle loss associated with semaglutide treatment. Lower doses were well tolerated, with 77% of participants experiencing at least one adverse event.
2. Next trial
The company plans a Phase 2 trial of trevogrumab with GLP-1 therapies in older adults.
